SantoSolve has presented additional 2PX clinical data at the Annual European Congress of Rheumatology, the annual conference of the European League Against Rheumatism
(EULAR), which took place from June 16 to June 19 in Rome, Italy. The poster "TOPICAL STRONTIUM (2PX) RELIEVES THE PAIN OF KNEE OSTEOARTHRITIS" (click here for download) was selected for one of the official EULAR Poster Tours and presented during the congress.

2PX is a first-in-class topical analgesic using non-radioactive strontium as the active substance. The drug is being developed for the relief of the signs and symptoms of osteoarthritis. The company expects to present data on a pivotal phase III trial in osteoarthritis during 3rd quarter 2010.

Download PDF: 2PX, a Topical Agent for Relief of Pain in Patients with OA

END

About SantoSolve:
SantoSolve is a privately held Norwegian biotech company, founded in 2002 and located in Oslo.

The company is developing targeted pain therapeutics, based on a novel class of active ingredients. The company's technology is covered by a broad range of patent applications, providing strong IPR protection.

For further information, please contact:

Thorfinn Ege, PhD, CEO | Tel: +47 - 907 95 494
Torgeir Vaage, PhD, CFO | Tel; +47 - 924 05 235

Website: www. santosolve.com